Lexaria reports promising drug delivery study results
KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX), a leader in drug delivery platforms with a market capitalization of $31.77 million, has announced significant advancements in its DehydraTECH ...
Le Lézard3h
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...
Rutgers University19h
A Weekly Injection Could Replace Painful Daily Treatment for Rare Fat Disorder
A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.
How to Play NVO Stock After New Drug's Success in Obesity Study
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Hosted on MSN2d
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...